Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KANT

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

ICYMI: Proteostasis Bear Call, eSports, Oracle's Q3, Roku Interview

Benzinga.com  March 21, 2018

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

PR Newswire March 20, 2018

Mid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis Therapeutics Shares Slide

Benzinga.com  March 20, 2018

28 Stocks Moving In Tuesday's Mid-Day Session

Benzinga.com  March 20, 2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proteostasis Therapeutics, Inc. - PTI

PR Newswire March 20, 2018

Mid-Day Market Update: Crude Oil Up 2.5%; Arena Pharmaceuticals Shares Spike Higher

Benzinga.com  March 20, 2018

Mid-Morning Market Update: Markets Gain; Oracle Shares Fall Following Q3 Results

Benzinga.com  March 20, 2018

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Micro Focus International plc (MFGP)

PR Newswire March 20, 2018

Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Proteostasis Therapeutics, Inc., and Announces Conference-Call Schedule

PR Newswire March 20, 2018

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  March 20, 2018

Benzinga Pro's 6 Stocks To Watch Today

Benzinga.com  March 20, 2018

Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire March 19, 2018

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Benzinga.com  March 16, 2018

Mid-Day Market Update: Dow Rises Over 200 Points; Invuity Shares Plummet

Benzinga.com  March 15, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  March 15, 2018

23 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 15, 2018

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

GlobeNewswire March 14, 2018

Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis

GlobeNewswire March 14, 2018

Mid-Afternoon Market Update: Commercial Vehicle Group Falls Following Q4 Results; Bovie Medical Shares Surge

Benzinga.com  March 13, 2018

Mid-Morning Market Update: Markets Open Higher; Dicks Sporting Goods Sales Miss Views

Benzinga.com  March 13, 2018